We identified TNFRSF9 (also known as 4-1BB or CD137), a previously reported target for enhancing antitumor immunity, among the final candidates for TI-Treg markers with high functional importance score. We found that the low TNFRSF9 expression level in Tregs was associated with enhanced ...
(12). 4-1BB can associate with OX40 on activated T cells, forming a complex that responds to either ligand and inhibits Treg and CD8+T cell proliferation (13). Reverse signaling through 4-1BB Ligand inhibits the development of dendritic cells, B cells, and osteoclasts (8, 11) but ...
activation, and/or survival of the 4-1BB expressing cell. It can also enhance the activation-induced cell death of repetitively stimulated T cells. 4-1BB can associate with OX40 on activated T cells, forming a complex that responds to either ligand and inhibits Treg and CD8+ T cell prolif...
(11). 4‑1BB can associate with OX40 on activated T cells, forming a complex that responds to either ligand and inhibits Treg and CD8+T cell proliferation (12). Reverse signaling through 4‑1BB Ligand inhibits the development of dendritic cells, B cells, and osteoclasts (6, 9) but ...
Yet, the influence of TNFRSF9 on Treg cells is controversial and TNFRSF9 has also been shown to maintain the suppressive capacity of Tregs [21,22]. As well as its expression on activated immune cells, TNFRSF9 is also expressed by inflamed or hypoxic endothelial cells [23] and has been ...
forming a complex that responds to either ligand and inhibits Treg and CD8+ T cell proliferation. Reverse signaling through 4-1BB Ligand inhibits the development of dendritic cells, B cells, and osteoclasts but supports mature dendritic cell survival and costimulates the proliferation and ac...